nodes	percent_of_prediction	percent_of_DWPC	metapath
Nebivolol—ADRB2—prostate cancer	0.556	1	CbGaD
Nebivolol—CYP2D6—Bicalutamide—prostate cancer	0.0583	0.504	CbGbCtD
Nebivolol—CYP2D6—Abiraterone—prostate cancer	0.0483	0.418	CbGbCtD
Nebivolol—CYP2D6—Doxorubicin—prostate cancer	0.00893	0.0773	CbGbCtD
Nebivolol—Skin disorder—Estradiol—prostate cancer	0.000322	0.00127	CcSEcCtD
Nebivolol—Rash—Ethinyl Estradiol—prostate cancer	0.00032	0.00126	CcSEcCtD
Nebivolol—Dermatitis—Ethinyl Estradiol—prostate cancer	0.00032	0.00126	CcSEcCtD
Nebivolol—Acute coronary syndrome—Capecitabine—prostate cancer	0.00032	0.00126	CcSEcCtD
Nebivolol—Headache—Ethinyl Estradiol—prostate cancer	0.000318	0.00125	CcSEcCtD
Nebivolol—Myocardial infarction—Capecitabine—prostate cancer	0.000318	0.00125	CcSEcCtD
Nebivolol—Renal failure acute—Epirubicin—prostate cancer	0.000317	0.00125	CcSEcCtD
Nebivolol—Hypersensitivity—Goserelin—prostate cancer	0.000308	0.00121	CcSEcCtD
Nebivolol—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000305	0.0012	CcSEcCtD
Nebivolol—Shock—Mitoxantrone—prostate cancer	0.000304	0.00119	CcSEcCtD
Nebivolol—Thrombocytopenia—Mitoxantrone—prostate cancer	0.000302	0.00119	CcSEcCtD
Nebivolol—Nausea—Ethinyl Estradiol—prostate cancer	0.000302	0.00119	CcSEcCtD
Nebivolol—Asthenia—Goserelin—prostate cancer	0.0003	0.00118	CcSEcCtD
Nebivolol—Skin disorder—Mitoxantrone—prostate cancer	0.0003	0.00118	CcSEcCtD
Nebivolol—Insomnia—Estradiol—prostate cancer	0.0003	0.00118	CcSEcCtD
Nebivolol—Erectile dysfunction—Prednisone—prostate cancer	0.000298	0.00117	CcSEcCtD
Nebivolol—Paraesthesia—Estradiol—prostate cancer	0.000298	0.00117	CcSEcCtD
Nebivolol—Asthenia—Conjugated Estrogens—prostate cancer	0.000297	0.00117	CcSEcCtD
Nebivolol—Bradycardia—Capecitabine—prostate cancer	0.000296	0.00116	CcSEcCtD
Nebivolol—Oedema peripheral—Docetaxel—prostate cancer	0.000296	0.00116	CcSEcCtD
Nebivolol—Pruritus—Goserelin—prostate cancer	0.000296	0.00116	CcSEcCtD
Nebivolol—Dyspnoea—Estradiol—prostate cancer	0.000296	0.00116	CcSEcCtD
Nebivolol—Somnolence—Estradiol—prostate cancer	0.000295	0.00116	CcSEcCtD
Nebivolol—Renal failure acute—Doxorubicin—prostate cancer	0.000294	0.00115	CcSEcCtD
Nebivolol—Pruritus—Conjugated Estrogens—prostate cancer	0.000293	0.00115	CcSEcCtD
Nebivolol—Oedema peripheral—Capecitabine—prostate cancer	0.000287	0.00113	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Estradiol—prostate cancer	0.000286	0.00112	CcSEcCtD
Nebivolol—Diarrhoea—Goserelin—prostate cancer	0.000286	0.00112	CcSEcCtD
Nebivolol—Fatigue—Estradiol—prostate cancer	0.000286	0.00112	CcSEcCtD
Nebivolol—Acute coronary syndrome—Prednisone—prostate cancer	0.000285	0.00112	CcSEcCtD
Nebivolol—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000283	0.00111	CcSEcCtD
Nebivolol—Myocardial infarction—Prednisone—prostate cancer	0.000283	0.00111	CcSEcCtD
Nebivolol—Vertigo—Etoposide—prostate cancer	0.000283	0.00111	CcSEcCtD
Nebivolol—Cardiac disorder—Docetaxel—prostate cancer	0.000279	0.0011	CcSEcCtD
Nebivolol—Paraesthesia—Mitoxantrone—prostate cancer	0.000277	0.00109	CcSEcCtD
Nebivolol—Loss of consciousness—Etoposide—prostate cancer	0.000277	0.00109	CcSEcCtD
Nebivolol—Dizziness—Goserelin—prostate cancer	0.000277	0.00109	CcSEcCtD
Nebivolol—Dyspnoea—Mitoxantrone—prostate cancer	0.000275	0.00108	CcSEcCtD
Nebivolol—Somnolence—Mitoxantrone—prostate cancer	0.000275	0.00108	CcSEcCtD
Nebivolol—Dizziness—Conjugated Estrogens—prostate cancer	0.000274	0.00108	CcSEcCtD
Nebivolol—Gastrointestinal pain—Estradiol—prostate cancer	0.000271	0.00107	CcSEcCtD
Nebivolol—Cardiac disorder—Capecitabine—prostate cancer	0.00027	0.00106	CcSEcCtD
Nebivolol—Chest pain—Etoposide—prostate cancer	0.000268	0.00105	CcSEcCtD
Nebivolol—Fatigue—Mitoxantrone—prostate cancer	0.000266	0.00105	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	0.000266	0.00105	CcSEcCtD
Nebivolol—Vomiting—Goserelin—prostate cancer	0.000266	0.00105	CcSEcCtD
Nebivolol—Aspartate aminotransferase increased—Epirubicin—prostate cancer	0.000264	0.00104	CcSEcCtD
Nebivolol—Bradycardia—Prednisone—prostate cancer	0.000264	0.00104	CcSEcCtD
Nebivolol—Rash—Goserelin—prostate cancer	0.000264	0.00104	CcSEcCtD
Nebivolol—Dermatitis—Goserelin—prostate cancer	0.000263	0.00104	CcSEcCtD
Nebivolol—Vomiting—Conjugated Estrogens—prostate cancer	0.000263	0.00104	CcSEcCtD
Nebivolol—Urticaria—Estradiol—prostate cancer	0.000263	0.00104	CcSEcCtD
Nebivolol—Mental disorder—Docetaxel—prostate cancer	0.000263	0.00103	CcSEcCtD
Nebivolol—Abdominal pain—Estradiol—prostate cancer	0.000262	0.00103	CcSEcCtD
Nebivolol—Headache—Goserelin—prostate cancer	0.000262	0.00103	CcSEcCtD
Nebivolol—Malnutrition—Docetaxel—prostate cancer	0.000262	0.00103	CcSEcCtD
Nebivolol—Rash—Conjugated Estrogens—prostate cancer	0.000261	0.00103	CcSEcCtD
Nebivolol—Dermatitis—Conjugated Estrogens—prostate cancer	0.000261	0.00103	CcSEcCtD
Nebivolol—Headache—Conjugated Estrogens—prostate cancer	0.00026	0.00102	CcSEcCtD
Nebivolol—Mental disorder—Capecitabine—prostate cancer	0.000255	0.001	CcSEcCtD
Nebivolol—Malnutrition—Capecitabine—prostate cancer	0.000253	0.000996	CcSEcCtD
Nebivolol—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000253	0.000993	CcSEcCtD
Nebivolol—Thrombocytopenia—Etoposide—prostate cancer	0.000252	0.000989	CcSEcCtD
Nebivolol—Skin disorder—Etoposide—prostate cancer	0.00025	0.000981	CcSEcCtD
Nebivolol—Nausea—Goserelin—prostate cancer	0.000248	0.000976	CcSEcCtD
Nebivolol—Nausea—Conjugated Estrogens—prostate cancer	0.000246	0.000967	CcSEcCtD
Nebivolol—Urticaria—Mitoxantrone—prostate cancer	0.000245	0.000964	CcSEcCtD
Nebivolol—Hypersensitivity—Estradiol—prostate cancer	0.000244	0.00096	CcSEcCtD
Nebivolol—Abdominal pain—Mitoxantrone—prostate cancer	0.000244	0.00096	CcSEcCtD
Nebivolol—Aspartate aminotransferase increased—Doxorubicin—prostate cancer	0.000244	0.00096	CcSEcCtD
Nebivolol—Asthenia—Estradiol—prostate cancer	0.000238	0.000935	CcSEcCtD
Nebivolol—Syncope—Docetaxel—prostate cancer	0.000235	0.000922	CcSEcCtD
Nebivolol—Pruritus—Estradiol—prostate cancer	0.000235	0.000922	CcSEcCtD
Nebivolol—Paraesthesia—Etoposide—prostate cancer	0.000231	0.000907	CcSEcCtD
Nebivolol—Loss of consciousness—Docetaxel—prostate cancer	0.00023	0.000904	CcSEcCtD
Nebivolol—Dyspnoea—Etoposide—prostate cancer	0.000229	0.0009	CcSEcCtD
Nebivolol—Somnolence—Etoposide—prostate cancer	0.000228	0.000898	CcSEcCtD
Nebivolol—Vertigo—Capecitabine—prostate cancer	0.000228	0.000894	CcSEcCtD
Nebivolol—Hypersensitivity—Mitoxantrone—prostate cancer	0.000228	0.000894	CcSEcCtD
Nebivolol—Syncope—Capecitabine—prostate cancer	0.000227	0.000893	CcSEcCtD
Nebivolol—Mental disorder—Prednisone—prostate cancer	0.000227	0.000893	CcSEcCtD
Nebivolol—Diarrhoea—Estradiol—prostate cancer	0.000227	0.000892	CcSEcCtD
Nebivolol—Malnutrition—Prednisone—prostate cancer	0.000226	0.000887	CcSEcCtD
Nebivolol—Chest pain—Docetaxel—prostate cancer	0.000223	0.000875	CcSEcCtD
Nebivolol—Loss of consciousness—Capecitabine—prostate cancer	0.000223	0.000875	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Etoposide—prostate cancer	0.000222	0.000872	CcSEcCtD
Nebivolol—Asthenia—Mitoxantrone—prostate cancer	0.000222	0.000871	CcSEcCtD
Nebivolol—Fatigue—Etoposide—prostate cancer	0.000222	0.000871	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.000221	0.000869	CcSEcCtD
Nebivolol—Dizziness—Estradiol—prostate cancer	0.000219	0.000862	CcSEcCtD
Nebivolol—Chest pain—Capecitabine—prostate cancer	0.000216	0.000848	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000214	0.000842	CcSEcCtD
Nebivolol—Diarrhoea—Mitoxantrone—prostate cancer	0.000211	0.000831	CcSEcCtD
Nebivolol—Vomiting—Estradiol—prostate cancer	0.000211	0.000828	CcSEcCtD
Nebivolol—Gastrointestinal pain—Etoposide—prostate cancer	0.00021	0.000826	CcSEcCtD
Nebivolol—Shock—Docetaxel—prostate cancer	0.00021	0.000826	CcSEcCtD
Nebivolol—Nervous system disorder—Docetaxel—prostate cancer	0.000209	0.000823	CcSEcCtD
Nebivolol—Thrombocytopenia—Docetaxel—prostate cancer	0.000209	0.000822	CcSEcCtD
Nebivolol—Rash—Estradiol—prostate cancer	0.000209	0.000822	CcSEcCtD
Nebivolol—Dermatitis—Estradiol—prostate cancer	0.000209	0.000821	CcSEcCtD
Nebivolol—Headache—Estradiol—prostate cancer	0.000208	0.000816	CcSEcCtD
Nebivolol—Skin disorder—Docetaxel—prostate cancer	0.000207	0.000815	CcSEcCtD
Nebivolol—Bradycardia—Epirubicin—prostate cancer	0.000206	0.000811	CcSEcCtD
Nebivolol—Angioedema—Prednisone—prostate cancer	0.000206	0.00081	CcSEcCtD
Nebivolol—Urticaria—Etoposide—prostate cancer	0.000204	0.000802	CcSEcCtD
Nebivolol—Shock—Capecitabine—prostate cancer	0.000203	0.000799	CcSEcCtD
Nebivolol—Abdominal pain—Etoposide—prostate cancer	0.000203	0.000798	CcSEcCtD
Nebivolol—Nervous system disorder—Capecitabine—prostate cancer	0.000203	0.000797	CcSEcCtD
Nebivolol—Vertigo—Prednisone—prostate cancer	0.000203	0.000797	CcSEcCtD
Nebivolol—Thrombocytopenia—Capecitabine—prostate cancer	0.000202	0.000796	CcSEcCtD
Nebivolol—Syncope—Prednisone—prostate cancer	0.000202	0.000795	CcSEcCtD
Nebivolol—Skin disorder—Capecitabine—prostate cancer	0.000201	0.000789	CcSEcCtD
Nebivolol—Oedema peripheral—Epirubicin—prostate cancer	0.0002	0.000785	CcSEcCtD
Nebivolol—Loss of consciousness—Prednisone—prostate cancer	0.000198	0.000779	CcSEcCtD
Nebivolol—Nausea—Estradiol—prostate cancer	0.000197	0.000774	CcSEcCtD
Nebivolol—Vomiting—Mitoxantrone—prostate cancer	0.000196	0.000772	CcSEcCtD
Nebivolol—Rash—Mitoxantrone—prostate cancer	0.000195	0.000765	CcSEcCtD
Nebivolol—Dermatitis—Mitoxantrone—prostate cancer	0.000195	0.000765	CcSEcCtD
Nebivolol—Headache—Mitoxantrone—prostate cancer	0.000194	0.000761	CcSEcCtD
Nebivolol—Insomnia—Docetaxel—prostate cancer	0.000193	0.000759	CcSEcCtD
Nebivolol—Paraesthesia—Docetaxel—prostate cancer	0.000192	0.000754	CcSEcCtD
Nebivolol—Bradycardia—Doxorubicin—prostate cancer	0.000191	0.000751	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000191	0.00075	CcSEcCtD
Nebivolol—Dyspnoea—Docetaxel—prostate cancer	0.00019	0.000748	CcSEcCtD
Nebivolol—Somnolence—Docetaxel—prostate cancer	0.00019	0.000746	CcSEcCtD
Nebivolol—Hypersensitivity—Etoposide—prostate cancer	0.000189	0.000744	CcSEcCtD
Nebivolol—Cardiac disorder—Epirubicin—prostate cancer	0.000188	0.000739	CcSEcCtD
Nebivolol—Insomnia—Capecitabine—prostate cancer	0.000187	0.000735	CcSEcCtD
Nebivolol—Paraesthesia—Capecitabine—prostate cancer	0.000186	0.00073	CcSEcCtD
Nebivolol—Oedema peripheral—Doxorubicin—prostate cancer	0.000185	0.000726	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000184	0.000725	CcSEcCtD
Nebivolol—Asthenia—Etoposide—prostate cancer	0.000184	0.000725	CcSEcCtD
Nebivolol—Dyspnoea—Capecitabine—prostate cancer	0.000184	0.000724	CcSEcCtD
Nebivolol—Fatigue—Docetaxel—prostate cancer	0.000184	0.000724	CcSEcCtD
Nebivolol—Nausea—Mitoxantrone—prostate cancer	0.000183	0.000721	CcSEcCtD
Nebivolol—Pruritus—Etoposide—prostate cancer	0.000182	0.000714	CcSEcCtD
Nebivolol—Shock—Prednisone—prostate cancer	0.000181	0.000712	CcSEcCtD
Nebivolol—Nervous system disorder—Prednisone—prostate cancer	0.000181	0.00071	CcSEcCtD
Nebivolol—Skin disorder—Prednisone—prostate cancer	0.000179	0.000703	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000179	0.000702	CcSEcCtD
Nebivolol—Fatigue—Capecitabine—prostate cancer	0.000178	0.000701	CcSEcCtD
Nebivolol—Mental disorder—Epirubicin—prostate cancer	0.000178	0.000698	CcSEcCtD
Nebivolol—Malnutrition—Epirubicin—prostate cancer	0.000176	0.000694	CcSEcCtD
Nebivolol—Diarrhoea—Etoposide—prostate cancer	0.000176	0.000691	CcSEcCtD
Nebivolol—Gastrointestinal pain—Docetaxel—prostate cancer	0.000175	0.000686	CcSEcCtD
Nebivolol—Cardiac disorder—Doxorubicin—prostate cancer	0.000174	0.000684	CcSEcCtD
Nebivolol—Dizziness—Etoposide—prostate cancer	0.00017	0.000668	CcSEcCtD
Nebivolol—Gastrointestinal pain—Capecitabine—prostate cancer	0.000169	0.000664	CcSEcCtD
Nebivolol—Abdominal pain—Docetaxel—prostate cancer	0.000169	0.000663	CcSEcCtD
Nebivolol—Insomnia—Prednisone—prostate cancer	0.000167	0.000655	CcSEcCtD
Nebivolol—Paraesthesia—Prednisone—prostate cancer	0.000165	0.00065	CcSEcCtD
Nebivolol—Mental disorder—Doxorubicin—prostate cancer	0.000164	0.000646	CcSEcCtD
Nebivolol—Urticaria—Capecitabine—prostate cancer	0.000164	0.000646	CcSEcCtD
Nebivolol—Abdominal pain—Capecitabine—prostate cancer	0.000163	0.000642	CcSEcCtD
Nebivolol—Vomiting—Etoposide—prostate cancer	0.000163	0.000642	CcSEcCtD
Nebivolol—Malnutrition—Doxorubicin—prostate cancer	0.000163	0.000642	CcSEcCtD
Nebivolol—Rash—Etoposide—prostate cancer	0.000162	0.000637	CcSEcCtD
Nebivolol—Dermatitis—Etoposide—prostate cancer	0.000162	0.000636	CcSEcCtD
Nebivolol—Headache—Etoposide—prostate cancer	0.000161	0.000633	CcSEcCtD
Nebivolol—Fatigue—Prednisone—prostate cancer	0.000159	0.000624	CcSEcCtD
Nebivolol—Vertigo—Epirubicin—prostate cancer	0.000159	0.000623	CcSEcCtD
Nebivolol—Syncope—Epirubicin—prostate cancer	0.000158	0.000622	CcSEcCtD
Nebivolol—Hypersensitivity—Docetaxel—prostate cancer	0.000157	0.000618	CcSEcCtD
Nebivolol—Loss of consciousness—Epirubicin—prostate cancer	0.000155	0.00061	CcSEcCtD
Nebivolol—Asthenia—Docetaxel—prostate cancer	0.000153	0.000602	CcSEcCtD
Nebivolol—Nausea—Etoposide—prostate cancer	0.000153	0.0006	CcSEcCtD
Nebivolol—Hypersensitivity—Capecitabine—prostate cancer	0.000152	0.000599	CcSEcCtD
Nebivolol—Pruritus—Docetaxel—prostate cancer	0.000151	0.000594	CcSEcCtD
Nebivolol—Gastrointestinal pain—Prednisone—prostate cancer	0.000151	0.000592	CcSEcCtD
Nebivolol—Chest pain—Epirubicin—prostate cancer	0.00015	0.00059	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.000149	0.000586	CcSEcCtD
Nebivolol—Asthenia—Capecitabine—prostate cancer	0.000148	0.000583	CcSEcCtD
Nebivolol—Vertigo—Doxorubicin—prostate cancer	0.000147	0.000577	CcSEcCtD
Nebivolol—Syncope—Doxorubicin—prostate cancer	0.000146	0.000576	CcSEcCtD
Nebivolol—Urticaria—Prednisone—prostate cancer	0.000146	0.000575	CcSEcCtD
Nebivolol—Pruritus—Capecitabine—prostate cancer	0.000146	0.000575	CcSEcCtD
Nebivolol—Diarrhoea—Docetaxel—prostate cancer	0.000146	0.000574	CcSEcCtD
Nebivolol—Abdominal pain—Prednisone—prostate cancer	0.000146	0.000572	CcSEcCtD
Nebivolol—Loss of consciousness—Doxorubicin—prostate cancer	0.000144	0.000564	CcSEcCtD
Nebivolol—Shock—Epirubicin—prostate cancer	0.000142	0.000557	CcSEcCtD
Nebivolol—Diarrhoea—Capecitabine—prostate cancer	0.000141	0.000556	CcSEcCtD
Nebivolol—Nervous system disorder—Epirubicin—prostate cancer	0.000141	0.000555	CcSEcCtD
Nebivolol—Dizziness—Docetaxel—prostate cancer	0.000141	0.000555	CcSEcCtD
Nebivolol—Thrombocytopenia—Epirubicin—prostate cancer	0.000141	0.000554	CcSEcCtD
Nebivolol—Skin disorder—Epirubicin—prostate cancer	0.00014	0.00055	CcSEcCtD
Nebivolol—Chest pain—Doxorubicin—prostate cancer	0.000139	0.000546	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	0.000138	0.000543	CcSEcCtD
Nebivolol—Dizziness—Capecitabine—prostate cancer	0.000137	0.000537	CcSEcCtD
Nebivolol—Vomiting—Docetaxel—prostate cancer	0.000136	0.000534	CcSEcCtD
Nebivolol—Hypersensitivity—Prednisone—prostate cancer	0.000136	0.000533	CcSEcCtD
Nebivolol—Rash—Docetaxel—prostate cancer	0.000135	0.000529	CcSEcCtD
Nebivolol—Dermatitis—Docetaxel—prostate cancer	0.000135	0.000529	CcSEcCtD
Nebivolol—Headache—Docetaxel—prostate cancer	0.000134	0.000526	CcSEcCtD
Nebivolol—Asthenia—Prednisone—prostate cancer	0.000132	0.000519	CcSEcCtD
Nebivolol—Vomiting—Capecitabine—prostate cancer	0.000131	0.000517	CcSEcCtD
Nebivolol—Shock—Doxorubicin—prostate cancer	0.000131	0.000515	CcSEcCtD
Nebivolol—Nervous system disorder—Doxorubicin—prostate cancer	0.000131	0.000514	CcSEcCtD
Nebivolol—Thrombocytopenia—Doxorubicin—prostate cancer	0.00013	0.000513	CcSEcCtD
Nebivolol—Rash—Capecitabine—prostate cancer	0.00013	0.000512	CcSEcCtD
Nebivolol—Pruritus—Prednisone—prostate cancer	0.00013	0.000512	CcSEcCtD
Nebivolol—Insomnia—Epirubicin—prostate cancer	0.00013	0.000512	CcSEcCtD
Nebivolol—Dermatitis—Capecitabine—prostate cancer	0.00013	0.000512	CcSEcCtD
Nebivolol—Headache—Capecitabine—prostate cancer	0.00013	0.000509	CcSEcCtD
Nebivolol—Skin disorder—Doxorubicin—prostate cancer	0.000129	0.000509	CcSEcCtD
Nebivolol—Paraesthesia—Epirubicin—prostate cancer	0.000129	0.000508	CcSEcCtD
Nebivolol—Dyspnoea—Epirubicin—prostate cancer	0.000128	0.000505	CcSEcCtD
Nebivolol—Somnolence—Epirubicin—prostate cancer	0.000128	0.000503	CcSEcCtD
Nebivolol—Nausea—Docetaxel—prostate cancer	0.000127	0.000499	CcSEcCtD
Nebivolol—Diarrhoea—Prednisone—prostate cancer	0.000126	0.000495	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000124	0.000489	CcSEcCtD
Nebivolol—Fatigue—Epirubicin—prostate cancer	0.000124	0.000488	CcSEcCtD
Nebivolol—Nausea—Capecitabine—prostate cancer	0.000123	0.000483	CcSEcCtD
Nebivolol—Dizziness—Prednisone—prostate cancer	0.000122	0.000479	CcSEcCtD
Nebivolol—Insomnia—Doxorubicin—prostate cancer	0.000121	0.000474	CcSEcCtD
Nebivolol—Paraesthesia—Doxorubicin—prostate cancer	0.00012	0.00047	CcSEcCtD
Nebivolol—Dyspnoea—Doxorubicin—prostate cancer	0.000119	0.000467	CcSEcCtD
Nebivolol—Somnolence—Doxorubicin—prostate cancer	0.000118	0.000466	CcSEcCtD
Nebivolol—Gastrointestinal pain—Epirubicin—prostate cancer	0.000118	0.000463	CcSEcCtD
Nebivolol—Vomiting—Prednisone—prostate cancer	0.000117	0.00046	CcSEcCtD
Nebivolol—Rash—Prednisone—prostate cancer	0.000116	0.000456	CcSEcCtD
Nebivolol—Dermatitis—Prednisone—prostate cancer	0.000116	0.000456	CcSEcCtD
Nebivolol—Headache—Prednisone—prostate cancer	0.000115	0.000453	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000115	0.000452	CcSEcCtD
Nebivolol—Fatigue—Doxorubicin—prostate cancer	0.000115	0.000452	CcSEcCtD
Nebivolol—Urticaria—Epirubicin—prostate cancer	0.000114	0.00045	CcSEcCtD
Nebivolol—Abdominal pain—Epirubicin—prostate cancer	0.000114	0.000447	CcSEcCtD
Nebivolol—Nausea—Prednisone—prostate cancer	0.000109	0.00043	CcSEcCtD
Nebivolol—Gastrointestinal pain—Doxorubicin—prostate cancer	0.000109	0.000428	CcSEcCtD
Nebivolol—Hypersensitivity—Epirubicin—prostate cancer	0.000106	0.000417	CcSEcCtD
Nebivolol—Urticaria—Doxorubicin—prostate cancer	0.000106	0.000416	CcSEcCtD
Nebivolol—Abdominal pain—Doxorubicin—prostate cancer	0.000105	0.000414	CcSEcCtD
Nebivolol—Asthenia—Epirubicin—prostate cancer	0.000103	0.000406	CcSEcCtD
Nebivolol—Pruritus—Epirubicin—prostate cancer	0.000102	0.0004	CcSEcCtD
Nebivolol—Diarrhoea—Epirubicin—prostate cancer	9.86e-05	0.000387	CcSEcCtD
Nebivolol—Hypersensitivity—Doxorubicin—prostate cancer	9.82e-05	0.000386	CcSEcCtD
Nebivolol—Asthenia—Doxorubicin—prostate cancer	9.56e-05	0.000376	CcSEcCtD
Nebivolol—Dizziness—Epirubicin—prostate cancer	9.52e-05	0.000374	CcSEcCtD
Nebivolol—Pruritus—Doxorubicin—prostate cancer	9.43e-05	0.000371	CcSEcCtD
Nebivolol—Vomiting—Epirubicin—prostate cancer	9.16e-05	0.00036	CcSEcCtD
Nebivolol—Diarrhoea—Doxorubicin—prostate cancer	9.12e-05	0.000358	CcSEcCtD
Nebivolol—Rash—Epirubicin—prostate cancer	9.08e-05	0.000357	CcSEcCtD
Nebivolol—Dermatitis—Epirubicin—prostate cancer	9.07e-05	0.000357	CcSEcCtD
Nebivolol—Headache—Epirubicin—prostate cancer	9.02e-05	0.000355	CcSEcCtD
Nebivolol—Dizziness—Doxorubicin—prostate cancer	8.81e-05	0.000346	CcSEcCtD
Nebivolol—Nausea—Epirubicin—prostate cancer	8.56e-05	0.000336	CcSEcCtD
Nebivolol—Vomiting—Doxorubicin—prostate cancer	8.47e-05	0.000333	CcSEcCtD
Nebivolol—Rash—Doxorubicin—prostate cancer	8.4e-05	0.00033	CcSEcCtD
Nebivolol—Dermatitis—Doxorubicin—prostate cancer	8.4e-05	0.00033	CcSEcCtD
Nebivolol—Headache—Doxorubicin—prostate cancer	8.35e-05	0.000328	CcSEcCtD
Nebivolol—Nausea—Doxorubicin—prostate cancer	7.92e-05	0.000311	CcSEcCtD
Nebivolol—ADRB2—Signaling Pathways—VAV3—prostate cancer	1.47e-05	0.000199	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—ITPR1—prostate cancer	1.46e-05	0.000197	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—JAK2—prostate cancer	1.45e-05	0.000197	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—TGFBR2—prostate cancer	1.45e-05	0.000196	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—MAP2K1—prostate cancer	1.45e-05	0.000196	CbGpPWpGaD
Nebivolol—ADRB1—GPCR downstream signaling—PIK3CB—prostate cancer	1.44e-05	0.000195	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—SULT2A1—prostate cancer	1.44e-05	0.000195	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—PIK3CD—prostate cancer	1.44e-05	0.000195	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—VAV3—prostate cancer	1.44e-05	0.000194	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—ITPR1—prostate cancer	1.43e-05	0.000193	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—TGFBR2—prostate cancer	1.42e-05	0.000192	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—MED12—prostate cancer	1.42e-05	0.000191	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—PIK3CB—prostate cancer	1.41e-05	0.000191	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—GNG5—prostate cancer	1.4e-05	0.00019	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—ITPR1—prostate cancer	1.39e-05	0.000189	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—IGF1R—prostate cancer	1.39e-05	0.000188	CbGpPWpGaD
Nebivolol—ADRB1—GPCR downstream signaling—CXCL8—prostate cancer	1.39e-05	0.000188	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—PIK3CB—prostate cancer	1.38e-05	0.000187	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—JAK2—prostate cancer	1.38e-05	0.000187	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—IGF1R—prostate cancer	1.36e-05	0.000184	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—CXCL8—prostate cancer	1.36e-05	0.000184	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—NCOA3—prostate cancer	1.35e-05	0.000183	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—JAK2—prostate cancer	1.35e-05	0.000183	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—LPL—prostate cancer	1.34e-05	0.000181	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—IGF1R—prostate cancer	1.33e-05	0.00018	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—CXCL8—prostate cancer	1.33e-05	0.000179	CbGpPWpGaD
Nebivolol—ADRB1—GPCR downstream signaling—IL2—prostate cancer	1.33e-05	0.000179	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—PDGFRB—prostate cancer	1.32e-05	0.000179	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—JAK2—prostate cancer	1.32e-05	0.000179	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—PIK3CB—prostate cancer	1.31e-05	0.000177	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—LPL—prostate cancer	1.31e-05	0.000177	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—IL2—prostate cancer	1.3e-05	0.000175	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—PDGFRB—prostate cancer	1.3e-05	0.000175	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—HPGDS—prostate cancer	1.29e-05	0.000175	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—ITGB3—prostate cancer	1.29e-05	0.000174	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—CYP2C19—prostate cancer	1.28e-05	0.000173	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—PIK3CB—prostate cancer	1.28e-05	0.000173	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—LPL—prostate cancer	1.28e-05	0.000173	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—IL2—prostate cancer	1.27e-05	0.000171	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—PDGFRB—prostate cancer	1.27e-05	0.000171	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—ITGB3—prostate cancer	1.26e-05	0.000171	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—CXCL8—prostate cancer	1.26e-05	0.00017	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—PIK3CB—prostate cancer	1.25e-05	0.00017	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—ACHE—prostate cancer	1.25e-05	0.000169	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—GSTT1—prostate cancer	1.25e-05	0.000169	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—ERBB3—prostate cancer	1.25e-05	0.000169	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—FGFR2—prostate cancer	1.25e-05	0.000169	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—CYP2A6—prostate cancer	1.24e-05	0.000167	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—ITGB3—prostate cancer	1.23e-05	0.000167	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—CXCL8—prostate cancer	1.23e-05	0.000167	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—ERBB3—prostate cancer	1.22e-05	0.000166	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—FGFR2—prostate cancer	1.22e-05	0.000165	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—CXCL8—prostate cancer	1.21e-05	0.000163	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—IL2—prostate cancer	1.2e-05	0.000163	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—AKR1C3—prostate cancer	1.2e-05	0.000163	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—TERT—prostate cancer	1.2e-05	0.000162	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—PRKACB—prostate cancer	1.2e-05	0.000162	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—ERBB3—prostate cancer	1.2e-05	0.000162	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—FGFR2—prostate cancer	1.2e-05	0.000162	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—CYP17A1—prostate cancer	1.19e-05	0.00016	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—IL2—prostate cancer	1.18e-05	0.000159	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—TERT—prostate cancer	1.17e-05	0.000159	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—IL2—prostate cancer	1.15e-05	0.000156	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—TERT—prostate cancer	1.15e-05	0.000155	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—HIF1A—prostate cancer	1.15e-05	0.000155	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—NCOA2—prostate cancer	1.13e-05	0.000153	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—HIF1A—prostate cancer	1.12e-05	0.000152	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—LEP—prostate cancer	1.12e-05	0.000151	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CAV1—prostate cancer	1.11e-05	0.00015	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—HIF1A—prostate cancer	1.1e-05	0.000148	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—KDR—prostate cancer	1.1e-05	0.000148	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—LEP—prostate cancer	1.1e-05	0.000148	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CAV1—prostate cancer	1.09e-05	0.000147	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—SLC5A5—prostate cancer	1.08e-05	0.000146	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—KDR—prostate cancer	1.07e-05	0.000145	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—LEP—prostate cancer	1.07e-05	0.000145	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—ESR1—prostate cancer	1.07e-05	0.000145	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CAV1—prostate cancer	1.06e-05	0.000144	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—CYP2E1—prostate cancer	1.05e-05	0.000142	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—KDR—prostate cancer	1.05e-05	0.000142	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—ESR1—prostate cancer	1.05e-05	0.000141	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—BAD—prostate cancer	1.04e-05	0.000141	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—NQO1—prostate cancer	1.04e-05	0.000141	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—TH—prostate cancer	1.03e-05	0.000139	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—ESR1—prostate cancer	1.02e-05	0.000138	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—BAD—prostate cancer	1.02e-05	0.000138	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—CYP3A4—prostate cancer	1.01e-05	0.000137	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—APC—prostate cancer	1.01e-05	0.000137	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—PIK3CG—prostate cancer	1.01e-05	0.000137	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—IRS1—prostate cancer	9.99e-06	0.000135	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—EGF—prostate cancer	9.99e-06	0.000135	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—BAD—prostate cancer	9.98e-06	0.000135	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—CYP1B1—prostate cancer	9.98e-06	0.000135	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—APC—prostate cancer	9.89e-06	0.000134	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—PIK3CG—prostate cancer	9.89e-06	0.000134	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—IRS1—prostate cancer	9.77e-06	0.000132	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—EGF—prostate cancer	9.77e-06	0.000132	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—GSK3B—prostate cancer	9.7e-06	0.000131	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—APC—prostate cancer	9.67e-06	0.000131	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—PIK3CG—prostate cancer	9.67e-06	0.000131	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—GGT1—prostate cancer	9.66e-06	0.000131	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—INS—prostate cancer	9.57e-06	0.000129	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—IRS1—prostate cancer	9.56e-06	0.000129	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—EGF—prostate cancer	9.56e-06	0.000129	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—NCOA1—prostate cancer	9.52e-06	0.000129	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—GSK3B—prostate cancer	9.49e-06	0.000128	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—CYP19A1—prostate cancer	9.38e-06	0.000127	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CREBBP—prostate cancer	9.37e-06	0.000127	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—INS—prostate cancer	9.36e-06	0.000127	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—GSK3B—prostate cancer	9.28e-06	0.000125	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—IGF1—prostate cancer	9.26e-06	0.000125	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—EGFR—prostate cancer	9.21e-06	0.000125	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CREBBP—prostate cancer	9.17e-06	0.000124	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—INS—prostate cancer	9.15e-06	0.000124	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—IGF1—prostate cancer	9.05e-06	0.000122	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—RXRA—prostate cancer	9.05e-06	0.000122	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—EGFR—prostate cancer	9.01e-06	0.000122	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CREBBP—prostate cancer	8.96e-06	0.000121	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—MAP2K1—prostate cancer	8.94e-06	0.000121	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—PIK3CD—prostate cancer	8.89e-06	0.00012	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—IGF1—prostate cancer	8.85e-06	0.00012	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—EGFR—prostate cancer	8.81e-06	0.000119	CbGpPWpGaD
Nebivolol—ADRB1—GPCR downstream signaling—PIK3CA—prostate cancer	8.8e-06	0.000119	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—SERPINE1—prostate cancer	8.79e-06	0.000119	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—MAP2K1—prostate cancer	8.75e-06	0.000118	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—COMT—prostate cancer	8.72e-06	0.000118	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—KRAS—prostate cancer	8.7e-06	0.000118	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—PIK3CD—prostate cancer	8.69e-06	0.000118	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—GSTP1—prostate cancer	8.68e-06	0.000117	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—PIK3CA—prostate cancer	8.61e-06	0.000116	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—SERPINE1—prostate cancer	8.6e-06	0.000116	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—MAP2K1—prostate cancer	8.56e-06	0.000116	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—ITPR1—prostate cancer	8.54e-06	0.000115	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—KRAS—prostate cancer	8.51e-06	0.000115	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—FGF2—prostate cancer	8.51e-06	0.000115	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—PIK3CD—prostate cancer	8.5e-06	0.000115	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—PIK3CA—prostate cancer	8.42e-06	0.000114	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—SERPINE1—prostate cancer	8.41e-06	0.000114	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—NOS3—prostate cancer	8.39e-06	0.000113	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—FGF2—prostate cancer	8.32e-06	0.000113	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—KRAS—prostate cancer	8.32e-06	0.000113	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—NOS3—prostate cancer	8.21e-06	0.000111	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—JAK2—prostate cancer	8.16e-06	0.00011	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—FGF2—prostate cancer	8.14e-06	0.00011	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—TYMS—prostate cancer	8.07e-06	0.000109	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—NOS3—prostate cancer	8.03e-06	0.000109	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—PIK3CA—prostate cancer	7.99e-06	0.000108	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—JAK2—prostate cancer	7.98e-06	0.000108	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—GSTM1—prostate cancer	7.98e-06	0.000108	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—MDM2—prostate cancer	7.96e-06	0.000108	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—ERBB2—prostate cancer	7.85e-06	0.000106	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—LPL—prostate cancer	7.83e-06	0.000106	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—PIK3CA—prostate cancer	7.82e-06	0.000106	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—JAK2—prostate cancer	7.8e-06	0.000105	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—MDM2—prostate cancer	7.79e-06	0.000105	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—PIK3CB—prostate cancer	7.75e-06	0.000105	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—ERBB2—prostate cancer	7.68e-06	0.000104	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—PIK3CA—prostate cancer	7.65e-06	0.000103	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—MDM2—prostate cancer	7.61e-06	0.000103	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—PIK3CB—prostate cancer	7.58e-06	0.000102	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—CYP1A1—prostate cancer	7.56e-06	0.000102	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—ERBB2—prostate cancer	7.51e-06	0.000102	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—ERCC2—prostate cancer	7.5e-06	0.000101	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CXCL8—prostate cancer	7.44e-06	0.000101	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—PIK3CB—prostate cancer	7.41e-06	0.0001	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CXCL8—prostate cancer	7.28e-06	9.84e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CDKN1B—prostate cancer	7.27e-06	9.83e-05	CbGpPWpGaD
Nebivolol—ADRB1—GPCR downstream signaling—AKT1—prostate cancer	7.19e-06	9.72e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CASP3—prostate cancer	7.12e-06	9.63e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CXCL8—prostate cancer	7.12e-06	9.63e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—IL2—prostate cancer	7.11e-06	9.62e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CDKN1B—prostate cancer	7.11e-06	9.61e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—IL6—prostate cancer	7.08e-06	9.57e-05	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—MTHFR—prostate cancer	7.05e-06	9.53e-05	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—AKT1—prostate cancer	7.03e-06	9.51e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CASP3—prostate cancer	6.97e-06	9.42e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—IL2—prostate cancer	6.96e-06	9.41e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CDKN1B—prostate cancer	6.95e-06	9.4e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CCND1—prostate cancer	6.93e-06	9.38e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—IL6—prostate cancer	6.92e-06	9.36e-05	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—PPARA—prostate cancer	6.91e-06	9.35e-05	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—AKT1—prostate cancer	6.88e-06	9.3e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CTNNB1—prostate cancer	6.87e-06	9.28e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CASP3—prostate cancer	6.81e-06	9.21e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—IL2—prostate cancer	6.8e-06	9.2e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CCND1—prostate cancer	6.78e-06	9.17e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—IL6—prostate cancer	6.77e-06	9.15e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—MMP9—prostate cancer	6.73e-06	9.1e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CTNNB1—prostate cancer	6.72e-06	9.08e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CDKN1A—prostate cancer	6.71e-06	9.07e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—PTEN—prostate cancer	6.69e-06	9.05e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CCND1—prostate cancer	6.63e-06	8.97e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—MMP9—prostate cancer	6.59e-06	8.9e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CTNNB1—prostate cancer	6.57e-06	8.88e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CDKN1A—prostate cancer	6.56e-06	8.87e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—PTEN—prostate cancer	6.55e-06	8.85e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—AKT1—prostate cancer	6.53e-06	8.83e-05	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—CAV1—prostate cancer	6.5e-06	8.79e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—MMP9—prostate cancer	6.44e-06	8.71e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CDKN1A—prostate cancer	6.42e-06	8.68e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—PTEN—prostate cancer	6.4e-06	8.66e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—AKT1—prostate cancer	6.39e-06	8.64e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—EP300—prostate cancer	6.38e-06	8.63e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—AKT1—prostate cancer	6.25e-06	8.44e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—EP300—prostate cancer	6.24e-06	8.44e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—SRC—prostate cancer	6.21e-06	8.39e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—EP300—prostate cancer	6.11e-06	8.25e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—SRC—prostate cancer	6.07e-06	8.21e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—VEGFA—prostate cancer	6.05e-06	8.17e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—STAT3—prostate cancer	5.99e-06	8.09e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—SRC—prostate cancer	5.94e-06	8.03e-05	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—PIK3CG—prostate cancer	5.92e-06	8.01e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—VEGFA—prostate cancer	5.91e-06	8e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—STAT3—prostate cancer	5.86e-06	7.92e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—VEGFA—prostate cancer	5.78e-06	7.82e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—STAT3—prostate cancer	5.73e-06	7.74e-05	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—INS—prostate cancer	5.61e-06	7.58e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—MYC—prostate cancer	5.56e-06	7.52e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—TGFB1—prostate cancer	5.55e-06	7.5e-05	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—CREBBP—prostate cancer	5.49e-06	7.42e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—MYC—prostate cancer	5.44e-06	7.36e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—EGFR—prostate cancer	5.44e-06	7.36e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—TGFB1—prostate cancer	5.43e-06	7.34e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—EGFR—prostate cancer	5.32e-06	7.2e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—MYC—prostate cancer	5.32e-06	7.19e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—TGFB1—prostate cancer	5.31e-06	7.18e-05	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—PIK3CD—prostate cancer	5.21e-06	7.04e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—EGFR—prostate cancer	5.2e-06	7.04e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—KRAS—prostate cancer	5.14e-06	6.95e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—KRAS—prostate cancer	5.03e-06	6.8e-05	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—NOS3—prostate cancer	4.92e-06	6.65e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—KRAS—prostate cancer	4.92e-06	6.65e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—PIK3CA—prostate cancer	4.72e-06	6.38e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—PIK3CA—prostate cancer	4.62e-06	6.24e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—TP53—prostate cancer	4.57e-06	6.18e-05	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—PIK3CB—prostate cancer	4.54e-06	6.14e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—PIK3CA—prostate cancer	4.52e-06	6.11e-05	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—PTGS2—prostate cancer	4.5e-06	6.08e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—TP53—prostate cancer	4.47e-06	6.04e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—TP53—prostate cancer	4.37e-06	5.91e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—IL6—prostate cancer	4.18e-06	5.65e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—IL6—prostate cancer	4.09e-06	5.53e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—IL6—prostate cancer	4e-06	5.41e-05	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—PTEN—prostate cancer	3.92e-06	5.3e-05	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—AKT1—prostate cancer	3.86e-06	5.22e-05	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—AKT1—prostate cancer	3.77e-06	5.1e-05	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—EP300—prostate cancer	3.74e-06	5.06e-05	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—AKT1—prostate cancer	3.69e-06	4.99e-05	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—PIK3CA—prostate cancer	2.77e-06	3.74e-05	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—AKT1—prostate cancer	2.26e-06	3.06e-05	CbGpPWpGaD
